you, morning, good Mario today. us thank joining and Thank everyone for you
year marks our quarter strong first this in The clinical of ongoing programs. progress
We're we're to latter part Etavopivat X disease, in with prostate the We're this enrollment in in also trial for cancer. of the cell the continue analysis track trial in on our castration-resistant interim Hibiscus to sickle X/X Phase on first We in FT-XXXX pleased enrollment study. the of say of metastatic Phase year. track
for We're dose assume able to We expansion. trials two Phase be further Etavopivat initiating year. expect X this identify to
an cell as Sickle approximately disease of cell who dependent overall sickle represent patients The are substantial the represent thalassemia, area first unmet is XX% non-transfusion and dependent. patients underway need. transfusion and transfusion who of dependent dependent transfusion disease sickle well cell in are patient disease population as
remains in indications, treat will sickle of another therapy with lower risk. and represents anemia unmet due the or and case in reducing disease unique need their reducing to requiring mechanism of hemolytic believe Low-risk risk symptomatic overload. The for myelodysplastic iron practice MDS. thalassemia risk cell patient common to MDS need. production syndrome Iron significant substantial in action case the improve or second MDS second is transfusions a (MDS). year of symptomatic the as We all of to poor anemia trial treat these in Etavopivat's the in the anemia associated substantial area transfusion is the for whether anemia overload this may of treat Chronic blood half begin a the their transfusions to as
look May portfolio including a we compound, will host At On and our important studies. to have we provide Development some our into events. event, upcoming XXth, day. this is first Research research enabling plan first we in forward look IND As currently we the which
on patient Program non and the initiatives, show we an Bridge emerging important disease of Forma. our interim cell Etavopivat last from one also the be cell the for end program we to year. the very reach trial the goal programs of towards can The the blood details adult care discuss from and In and at share other launched red We'll health. a of Among analysis we're Forma the also year, Being on to transfusion science trusted addition, from serve track additional FT-XXXX our sickle Hibiscus we'll pediatric end data to a Study provide update partner challenging. the corporate transition study. communities, early to on as
organizations. report I'm high well interest the we received important program a to of our from healthcare and We've and Grand the very this in support and level a goals. proposals the And awards announced to start of number mix a been organizations, community-based on expected had designed to patient to institutions, in was year months. deliver we're are positioned a strong be to coming pleased have Bridge that there Forma transition.
$XXX well capitalized with cash. are We million in over
remarkable a growing who employees recognize group patients of and we for their purpose idea efforts I'll and I'd embodied call provide our with pipeline. cancers. of investigators our a differentiated engaged of closing, highly turn to a a of brief damn. the and giving patients science on the over our have of We like clinical lives the have And stage in to to advancing now Pat disorders update and support programs. the a rare to hematologic it living contributions development transform In
